SCIEX-RedShiftBio partnership expands MMS reach, addresses challenges in biotherapeutic structural analysis
SCIEX to provide Microfluidic Modulation Spectroscopy (MMS) solutions for in-depth characterization of key attributes of biotherapeutics
November 16, 2021
Framingham, MA and Burlington, MA — SCIEX, a global leader in life science analytical technologies, and RedShiftBio®, a provider of next-generation platform technology enabling measurements of previously undetectable structure changes in biomolecules, have entered into a supply relationship to help more biopharmaceutical labs access the critical data necessary to close the developability gap. This agreement will enable SCIEX to resell the AQS3®profrom RedShiftBio throughout the United States, alongside its market-leading CE and LC-MS solutions.
The AQS³pro’s novel MMS technology allows users fast, ultra-sensitive, and accurate analysis of biomolecules’ higher order structure. This unique technology integrates automated sample handling with a unique microfluidic system and a quantum cascade laser based optical system to dramatically improve the resolution, repeatability, data quality, precision and accuracy of IR spectroscopy.
“I am thrilled that RedShiftBio has found such a strong partner in SCIEX. Their continuous drive for innovation and commercial reach into the biopharmaceutical development segment will further accelerate access to MMS technology. Together, these complementary solutions will help customers optimize their drug development workflows and ultimately make better drugs, faster,” said Julien Bradley, Chief Executive Officer of RedShiftBio.
Key features of the AQS³pro instrument include:
· Ultra-sensitive, highly precise and reproducible measurements of higher order structure of proteins, nucleic acids, and other biomolecules
· Detection of <2% change in secondary structure even at low concentrations
· Ability to measure wide range of native sample concentrations from <0.1 mg/ml to >200 mg/ml
· Fully automated sample-handling, with both 24- and 96-wellplate formats
· Real-time background subtraction eliminates need to dialyze samples
· Advanced onboard data analytics enabling rapid and robust data interpretation and reporting
Biopharma labs are under tremendous pressure to speed new biotherapeutics to market. In order to avoid time-consuming and expensive failures in development, they need to characterize the key attributes of their molecules as early as possible in discovery.
“The AQS³pro delivers the ability to rapidly measure the secondary structure of a protein, which can be crucial to understanding how well that molecule will perform and behave under manufacturing conditions,” said Mani Krishnan, Vice President, and General Manager, CE & Biopharma, at SCIEX. “This relationship is another example of how SCIEX, along with our market-leading CE and LC-MS workflows, is dedicated to providing our customers confidence in their results and helping them close the developability gap.”
To learn more about the AQS³pro, see here.
SCIEX delivers solutions for the precision detection and quantification of molecules, empowering our customers to protect and advance the wellness and safety of all. We have been at the forefront of the field of mass spectrometry for 50 years. From the launch of the first ever commercially successful triple quadrupole in 1981, we have developed groundbreaking technologies and solutions that influence life-changing research and outcomes.
Today, we continue to pioneer robust solutions in mass spectrometry and capillary electrophoresis. Our customers can quickly respond to environmental hazards, better understand biomarkers relevant to disease, improve patient care in the clinic, bring relevant drugs to market faster and keep food healthier and safer.
That’s why thousands of life science experts around the world choose SCIEX to get the answers they can trust to better inform critical decisions that positively impact lives.
For more information, visit sciex.com.
Let’s connect: Twitter, LinkedIn, Facebook and Instagram.
Advances in human wellness depend on the power of precise science.
RedShiftBio is a forward-thinking technology company providing a novel life sciences platform for reliable and accurate detection of pivotal changes in molecular structure that affect the critical quality attributes governing the safety, efficacy, and stability of biomolecules and their raw materials. The company has developed a powerful new analytical technique, Microfluidic Modulation Spectroscopy (MMS), that provides in-depth structural information in a single automated analysis. RedShiftBio is headquartered out of Burlington, Massachusetts. For more information, please visit www.redshiftbio.com.
Let’s connect: LinkedIn
Lulu Van Zandt
Senior Manager, Brand, Public Relations and Social Media
M: +1 (508) 782-9484
Director, Marketing and Communications
The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to www.sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures.
Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see www.sciex.com/trademarks).
Echo and Echo MS are trademarks or registered trademarks of Labcyte, Inc. in the United States and other countries, and are being used under license.
© 2021 DH Tech. Dev. Pte. Ltd. RUO-MKT-12-14125-A